DEINOVE continues to structure its health activities and welcomes Dr Bernard Scorneaux as preclinical project manager
Specialist in pharmacology and preclinical studies in infectious diseases, Dr Bernard Scorneaux has led the studies of several drug candidates currently on the market or in advanced clinical development.
Montpellier, 21 March 2017 (6:30PM CET) - DEINOVE (Alternext Paris: ALDEI), a biotech company that discovers, develops and produces high-value compounds from rare bacteria, notably from the Deinococcus genus, announces the appointment of Dr Bernard Scorneaux to prepare and manage preclinical studies on the antibiotic compounds developed by the Company.
Bernard Scorneaux, PhD, has 20 years of experience in research in infectious diseases, including 15 years in the United States. Specialist in the development of anti-infective drugs, his expertise extends to the entire development process, from design, implementation, and follow-up of preclinical and early clinical studies (Phase I) to the drafting of regulatory documents. He has contributed actively to the development of several first-in-class drug candidates in Europe and the United States, including antifungals, antibiotics and antiretrovirals. Actively involved in the Malaria for Medicine Venture program, he participated in the development of Arterolane, an antimalarial drug responding to a real public health issue, placed on the African market in 2015.
Before joining DEINOVE, Dr Scorneaux managed several programs and teams within Eyevensys, Scynexis, Enanta and the Swiss Tropical Institute.
Bernard Scorneaux holds a PhD in biology, pharmacokinetics and microbiology from the Université catholique de Louvain, Belgium.
"We are very pleased to announce the arrival of Bernard Scorneaux in our team. The fact that he chose to put his expertise and experience into DEINOBIOTICS demonstrates the credibility of our project and the quality of our approach. Dr Scorneaux will manage the preclinical development of our first candidate and structure the activity to allow the simultaneous development of several leads," stated Dominique Le Beller, CEO of DEINOBIOTICS.
Emmanuel Petiot, CEO of DEINOVE, added: "The arrival of Bernard Scorneaux marks an important step in the strategic focus of the company on health activities. His contribution will be significant and his experience invaluable, particularly in the development of new antibiotic families."
Bernard Scorneaux commented: "I am delighted to join the Company at this exciting stage of its development and contribute to 'converting the try': to turn preclinical compounds into treatments that change the lives of patients."
PR in English
CP en français